Other approaches to inhibiting PRC2 activity in cancer include a staple peptide inhibitor that disrupts the protein-protein interaction (PPI) of EZH2-EED, with significant antiproliferative functions even in cells resistant to EZH2 inhibitors [281]. This evidence concerns the gene EED and cancer.